| Symbol | ACAD |
|---|---|
| Name | ACADIA PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 12830 EL CAMINO REAL, SAN DIEGO, CA 92130 |
| Telephone | 858-558-2871 |
| Fax | — |
| — | |
| Website | https://www.acadia.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001070494 |
| Description | Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinsons, Alzheimers, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The companys patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. Additional info from NASDAQ: |
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimers Disease Psychosis
Read moreKihara James 🔴 sold 11.4K shares of ACADIA PHARMACEUTICALS INC (ACAD) at $26.08 Transaction Date: Jun 26, 2026 | Filing ID: 000009
Read moreDAYBU® (trofinetyd) zalecany w UE przez CHMP do stosowania w leczeniu zespołu Retta
Read more📋 Kihara James (Officer) plans to sell 11K shares of ACADIA PHARMACEUTICALS INC (at $26.00 each, total $297K) Filed: Jun 26, 2026 | ID: 000036
Read moreDAYBU® (trofinetida) recibe una recomendación positiva por parte del CHMP para su aprobación en la Unión Europea
Read moreMalattie rare – Dal CHMP parere positivo per trofinetide per il trattamento della sindrome di Rett
Read moreDAYBU® (Trofinetide) vom CHMP für die Zulassung in der Europäischen Union empfohlen
Read moreDAYBU® (trofinétide) recommandé dans l’UE par le CHMP pour le traitement du syndrome de Rett
Read moreDAYBU® (trofinetide) in de EU aanbevolen door CHMP voor de behandeling van het Rett-syndroom
Read more